Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords

Tabla de Datos

Artículos Totales: 18


Institución: Oncovida Canc Ctr
# Título Código Publicación Revista Indexación Revista Tipo de Documento Autores Año
1 Pembrolizumab Plus Chemotherapy For Advanced And Recurrent Cervical Cancer: Final Analysis According To Bevacizumab Use In The Randomized Keynote 826 Study
DOI: 10.1016/J.ANNONC.2024.10.002 		WoS: WOS:001425024900001 Scopus: SCOPUS_ID:85209554981 Annals Of Oncology WOS
Scopus 		Article 2025
2 Patient Reported Outcomes From The Phase 3, Randomized, Double Blind, Placebo Controlled Engot Cx11/Gog 3047/Keynote A18 Study Of Pembrolizumab Plus Concurrent Chemoradiotherapy In Patients With High Risk Locally Advanced Cervical Cancer
DOI: 10.1136/IJGC-2024-ESGO.53 		WoS: WOS:001444808900027 International Journal Of Gynecological Cancer WOS
Meeting Abstract 2024
3 Patient Reported Outcomes From The Phase Iii, Randomized, Double Blind, Placebo Controlled Engot Cx11/Gog 3047/ Keynote A18 Study Of Pembrolizumab Plus Concurrent Chemoradiotherapy Among Patients With High Risk, Locally Advanced Cervical Cancer
WoS: WOS:001330731400011 Gynecologic Oncology WOS
Meeting Abstract 2024
4 Association Of Biomarkers With Response To First Line (1 L) Vibostolimab (Anti Tigit) Coformulated With Pembrolizumab (Vibo/Pembro) In Advanced Head And Neck Squamous Cell Carcinoma (Hnscc): Results From Keyvibe 005
DOI: 10.1016/J.ANNONC.2024.08.969 		WoS: WOS:001326612901213 Annals Of Oncology WOS
Meeting Abstract 2024
5 Pembrolizumab Or Placebo Plus Chemotherapy With Or Without Bevacizumab For Persistent, Recurrent, Or Metastatic Cervical Cancer: Subgroup Analyses From The Keynote 826 Randomized Clinical Trial
DOI: 10.1001/JAMAONCOL.2023.5410 		WoS: WOS:001412748700001 Scopus: SCOPUS_ID:85180927388 Jama Oncology WOS
Scopus 		Article 2024
6 Addressing The Unmet Needs Of Patients With Braf Mutated Melanoma In Latin America: Expert Perspective
DOI: 10.3389/FONC.2023.1032300 		WoS: WOS:000983485200001 Scopus: SCOPUS_ID:85150938883 Frontiers In Oncology WOS
Scopus 		Review 2023
7 Health Related Quality Of Life With Pembrolizumab Or Placebo Plus Chemotherapy With Or Without Bevacizumab For Persistent, Recurrent, Or Metastatic Cervical Cancer (Keynote 826): A Randomised, Double Blind, Placebo Controlled, Phase 3 Trial
DOI: 10.1016/S1470-2045(23)00052-9 		WoS: WOS:000967097700001 Scopus: SCOPUS_ID:85150906101 Lancet Oncology WOS
Scopus 		Article 2023
8 Keynote 826: Final Overall Survival Results From A Randomized, Double Blind, Phase 3 Study Of Pembrolizumab Plus Chemotherapy Vs Placebo Plus Chemotherapy For First Line Treatment Of Persistent, Recurrent, Or Metastatic Cervical Cancer
WoS: WOS:001053772003016 Journal Of Clinical Oncology WOS
Meeting Abstract 2023
9 First Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy For Persistent, Recurrent, Or Metastatic Cervical Cancer: Final Overall Survival Results Of Keynote 826
DOI: 10.1200/JCO.23.00914 		WoS: WOS:001133443400001 Scopus: SCOPUS_ID:85178116765 Journal Of Clinical Oncology WOS
Scopus 		Article 2023
10 Keynote 826: Final Overall Survival Results From A Randomized, Double Blind, Phase 3 Study Of Pembrolizumab Plus Chemotherapy Vs Placebo Plus Chemotherapy For First Line Treatment Of Persistent, Recurrent, Or Metastatic Cervical Cancer
DOI: 10.1136/IJGC-2023-ESGO.886 		WoS: WOS:001264297900887 International Journal Of Gynecological Cancer WOS
Meeting Abstract 2023
11 Pembrolizumab Plus Chemotherapy For First Line Treatment Of Patients With Persistent, Recurrent, Or Metastatic Cervical Cancer: Bevacizumab Subgroup Analysis Based On Protocol Specified Final Overall Survival Results Of Keynote 826
DOI: 10.1136/IJGC-2023-ESGO.1 		WoS: WOS:001264297900002 International Journal Of Gynecological Cancer WOS
Meeting Abstract 2023
12 Pembrolizumab Plus Chemotherapy In Persistent, Recurrent, Or Metastatic Cervical Cancer: A Keynote 826 Subgroup Analysis
WoS: WOS:000871956500161 Asia Pacific #Journal Of Clinical Oncology WOS
Meeting Abstract 2022
13 Pembrolizumab Plus Chemotherapy In Patients With Persistent, Recurrent, Or Metastatic Cervical Cancer: Subgroup Analysis Of Keynote 826.
WoS: WOS:000863680301558 Journal Of Clinical Oncology WOS
Meeting Abstract 2022
14 Patient Reported Outcomes From The Phase 3 Randomized, Double Blind, Keynote 826 Trial Of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy For The First Line Treatment Of Persistent, Recurrent, Or Metastatic Cervical Cancer
WoS: WOS:000892325300025 Gynecologic Oncology WOS
Meeting Abstract 2022
15 Pembrolizumab For Persistent, Recurrent, Or Metastatic Cervical Cancer
DOI: 10.1097/01.OGX.0000805152.09501.F1 		WoS: WOS:000739995400015 Scopus: SCOPUS_ID:85123362104 Obstetrical & Gynecological Survey WOS
Scopus 		Editorial Material 2022
16 Pembrolizumab For Persistent, Recurrent, Or Metastatic Cervical Cancer
DOI: 10.1056/NEJMOA2112435 		WoS: WOS:000697035300001 Scopus: SCOPUS_ID:85116462150 New England Journal Of Medicine WOS
Scopus 		Article 2021
17 Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy For Persistent, Recurrent, Or Metastatic Cervical Cancer: Randomized, Double Blind, Phase Iii Keynote 826 Study
DOI: 10.1016/J.ANNONC.2021.08.2108 		WoS: WOS:000700527703507 Annals Of Oncology WOS
Meeting Abstract 2021
18 Keynote 826: Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy For Persistent, Recurrent, Or Metastatic Cervical Cancer
DOI: 10.1136/IJGC-2021-ESGO.641 		WoS: WOS:000773543202143 International Journal Of Gynecological Cancer WOS
Meeting Abstract 2021
Descargar Descarga los datos (enriquecidos) de esta página (formato CSV).









Departamento Gestión de Conocimiento, Monitoreo y Prospección
 Moneda 1375, Santiago de Chile. Teléfono (56 2) 2365 4400
Consultas o comentarios: productividad@anid.cl